European Journal of Cardiovascular Medicine

Background: Hepatitis C virus (HCV) infection remains a major public health concern, with more than 100 million people chronically infected worldwide.Direct acting antivirals have revolutionized the treatment landscape for patients with chronic hepatitis C because they have been shown to demonstrate high SVR rates. Objectives: To see effectiveness of Hepatitis C treatment with DAA in CKD and Non-CKD patients in terms of effect on viral load / SVR. Methodology: Medical records of registered hepatitis C positive patients from the Model Treatment Center (MTC) under National Viral Hepatitis Control Programe (NVHCP) MoHFW GOI were taken. HCV Positive patients who have completed DAA Therapy and who have passed at least 12 week after completion of therapy were included. Results: We gave regimen 1 to 29.09% patients while regimen 2 was given to 67.2% patients and regimen 3 was given to 1.82% patients.We found that with regimen 2, 65.4% SVR rate were recorded with 1.82% therapeutic failure. The SVR rate of 29.09% found with regime 1 while 1.8% SVR rate recorded with R3 regime.SVR rate of 63.6% seen after 12 week of treatment while 34.5% SVR rate was observed after 24 week treatment.We found that 97.1% SVR rate was observed in patients with duration of treatment upto 12 week while 100% SVR rate was observed in 24 week treatment time.We found that in patients with CKD 36.3% SVR rate was achieved while in patients without CKD 60% SVR rate was achieved. Conclusions: It is important to note that the high rate of effectiveness about 95% in all age group with the second-generation DAAs, and declined in viral load in more than 99% patients and SVR achieved in about 98% patients after 12-week or 24-week treatment and SVR more achieved in patients without CKD than patients with CKD,  establishing these antivirals as safe and well-tolerated drugs.